ORZEYFUL approved in China for narcolepsy type 1
KEY STEPChina’s National Medical Products Administration approved ORZEYFUL, or oveporexton, for the treatment of narcolepsy type 1 in patients aged 16 years and older and adults.
Roadmap referenceTakeda Pharmaceutical Company Limited engages in the research, development, manufacture, market...
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
China’s National Medical Products Administration approved ORZEYFUL, or oveporexton, for the treatment of narcolepsy type 1 in patients aged 16 years and older and adults.
Roadmap referenceThe United States Food and Drug Administration approved ORZEYFUL, or oveporexton, for adults with narcolepsy type 1, marking the first approved treatment designed to restore orexin signaling and address the underlying cause of the disorder.
Roadmap referenceJapan’s Ministry of Health, Labour and Welfare approved ORZEYFUL for adults with narcolepsy type 1, giving the medicine its third major regulatory approval.
Roadmap referenceThe United States Food and Drug Administration approved MIMRYLO, or rusfertide, for the treatment of erythrocytosis in adults with polycythemia vera.
Roadmap referenceIndependent External Director
Company leadership profile.
Independent External Chair
Company leadership profile.
CEO, President & Director
Company leadership profile.
CFO & Director
Company leadership profile.
President of Research & Development and Representative Director
Company leadership profile.
Independent External Director
Company leadership profile.
Independent External Director
Company leadership profile.
Independent External Director
Company leadership profile.
Independent External Director
Company leadership profile.
Independent External Director
Company leadership profile.
Independent External Director
Company leadership profile.
1 expert evaluated Takeda Pharmaceutical Co.
Explore the public profiles of experts who have evaluated this project.
Orbitrum Academy